相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PUFA-Induced Metabolic Enteritis as a Fuel for Crohn's Disease
Julian Schwaerzler et al.
GASTROENTEROLOGY (2022)
Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity
Ahmed Ghallab et al.
JOURNAL OF HEPATOLOGY (2022)
Dietary lipids from body to brain
Custers et al.
PROGRESS IN LIPID RESEARCH (2022)
Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases
Baoyi Guan et al.
ACTA PHARMACEUTICA SINICA B (2022)
FXR: structures, biology, and drug development for NASH and fibrosis diseases
Si-yu Tian et al.
ACTA PHARMACOLOGICA SINICA (2022)
Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR/SHP pathway
Tianwei Zhang et al.
ARCHIVES OF TOXICOLOGY (2022)
Mesenchymal stem cells protect against ferroptosis via exosome-mediated stabilization of SLC7A11 in acute liver injury
Feiyan Lin et al.
CELL DEATH & DISEASE (2022)
Cooperative action of gut-microbiota-accessible carbohydrates improves host metabolic function
Sawako Tomioka et al.
CELL REPORTS (2022)
An overview of ferroptosis in non-alcoholic fatty liver disease
Shendong Wang et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Chenodeoxycholic acid suppresses AML progression through promoting lipid peroxidation via ROS/p38 MAPK/DGAT1 pathway and inhibiting M2 macrophage polarization
Jinting Liu et al.
REDOX BIOLOGY (2022)
Fluorescent Egg White-Based Carbon Dots as a High-Sensitivity Iron Chelator for the Therapy of Nonalcoholic Fatty Liver Disease by Iron Overload in Zebrafish
Lidong Yu et al.
ACS APPLIED MATERIALS & INTERFACES (2021)
Nonalcoholic fatty liver disease: another leap forward
Manal F. Abdelmalek
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Broadening horizons: the role of ferroptosis in cancer
Xin Chen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer
Lulu Sun et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Rohit Loomba et al.
CELL (2021)
Cross-talk between hepatic stellate cells and T lymphocytes in liver fibrosis
Hao Li et al.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2021)
Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions
Maria Notarnicola et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption
Bethan L. Clifford et al.
CELL METABOLISM (2021)
Peroxidation of n-3 and n-6 polyunsaturated fatty acids in the acidic tumor environment leads to ferroptosis-mediated anticancer effects
Emeline Dierge et al.
CELL METABOLISM (2021)
A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage
Suling Huang et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2021)
HP1021 is a redox switch protein identified in Helicobacter pylori
Piotr Szczepanowski et al.
NUCLEIC ACIDS RESEARCH (2021)
Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics
Anna Di Sessa et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2021)
Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice
Wen-Cong Li et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2021)
Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice
Yunhuan Liu et al.
HEPATOLOGY (2020)
SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
Jiyu Zhou et al.
NATURE COMMUNICATIONS (2020)
TGFβ2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells
Cyril Corbet et al.
NATURE COMMUNICATIONS (2020)
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
Kris Kowdley et al.
JOURNAL OF HEPATOLOGY (2020)
Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis
Cristina Lopez-Vicario et al.
JOURNAL OF HEPATOLOGY (2020)
Lytic cell death in metabolic liver disease
Jeremie Gautheron et al.
JOURNAL OF HEPATOLOGY (2020)
PEBP1 acts as a rheostat between prosurvival autophagy and ferroptotic death in asthmatic epithelial cells
Jinming Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Ferroptosis mediated by the interaction between Mfn2 and IREα promotes arsenic-induced nonalcoholic steatohepatitis
Sen Wei et al.
ENVIRONMENTAL RESEARCH (2020)
Obeticholic acid may increase the risk of gallstone formation in susceptible patients
Samer Al-Dury et al.
JOURNAL OF HEPATOLOGY (2019)
Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis
Shinya Tsurusaki et al.
CELL DEATH & DISEASE (2019)
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
Norbert Stefan et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Obeticholic acid: towards first approval for NASH
Mohammed Eslam et al.
LANCET (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Taxonomic profiling and populational patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome
Ziwei Song et al.
MICROBIOME (2019)
Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
Jiyu Zhou et al.
ACTA PHARMACEUTICA SINICA B (2019)
FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
Xiaoxin X. Wang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
Wei Jia et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model
Francois Briand et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis
Giovanni Musso et al.
GASTROENTEROLOGY (2018)
Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches
Antonella Borrelli et al.
REDOX BIOLOGY (2018)
Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease
Natalia Wasilewska et al.
LIPIDS IN HEALTH AND DISEASE (2018)
Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC
Marcus Grohmann et al.
CELL (2018)
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin
Lulu Sun et al.
NATURE MEDICINE (2018)
FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis
Rowan F. van Golen et al.
SCIENTIFIC REPORTS (2018)
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Yaron Rotman et al.
GUT (2017)
Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis
Valerian E. Kagan et al.
NATURE CHEMICAL BIOLOGY (2017)
Redox signaling mediated by the gut microbiota
Rheinallt M. Jones et al.
FREE RADICAL BIOLOGY AND MEDICINE (2017)
Mechanisms of hepatic stellate cell activation
Takuma Tsuchida et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice
Hani Jouihan et al.
MOLECULAR METABOLISM (2017)
Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers
R. Pencek et al.
DIABETES OBESITY & METABOLISM (2016)
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Giovanni Musso et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
Gideon M. Hirschfield et al.
GASTROENTEROLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Changtao Jiang et al.
NATURE COMMUNICATIONS (2015)
Polyunsaturated fatty acids and their metabolites in brain function and disease
Richard P. Bazinet et al.
NATURE REVIEWS NEUROSCIENCE (2014)
Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Hannele Yki-Jarvinen
LANCET DIABETES & ENDOCRINOLOGY (2014)
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Sunder Mudaliar et al.
GASTROENTEROLOGY (2013)
Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism
Claudia O. Zein et al.
HEPATOLOGY (2012)
Reactive Oxygen Species Induced by Bile Acid Induce Apoptosis and Protect Against Necrosis in Pancreatic Acinar Cells
David M. Booth et al.
GASTROENTEROLOGY (2011)
Relationship Between the Pattern of Hepatic Iron Deposition and Histological Severity in Nonalcoholic Fatty Liver Disease
James E. Nelson et al.
HEPATOLOGY (2011)
Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
Xiaoxin X. Wang et al.
DIABETES (2010)
The role of the gut microbiota in nonalcoholic fatty liver disease
Ahmed Abu-Shanab et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
The Plasma Lipidomic Signature of Nonalcoholic Steatohepatitis
Puneet Puri et al.
HEPATOLOGY (2009)
Sphingolipids, insulin resistance, and metabolic disease:: New insights from in vivo manipulation of sphingolipid metabolism
William L. Holland et al.
ENDOCRINE REVIEWS (2008)
A lipidomic analysis of nonalcoholic fatty liver disease
Puneet Puri et al.
HEPATOLOGY (2007)
Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration
WD Huang et al.
SCIENCE (2006)
Farnesoid X receptor is essential for normal glucose homeostasis
K Ma et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death
CP Baines et al.
NATURE (2005)
Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR
YQ Zhang et al.
GENES & DEVELOPMENT (2004)
The gut microbiota as an environmental factor that regulates fat storage
F Bäckhed et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis
CJ Sinal et al.
CELL (2000)
分享论文
